Advisors Asset Management, Inc. Clovis Oncology, Inc. Transaction History

Advisors Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $42,465 - $85,096	-3,315 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $19,920 - $34,155	-1,128 Reduced 25.39%	3,315 $82,000
Q4 2018 Jan 31, 2019	SELL	$11.63 - $32.67 $1,616 - $4,541	-139 Reduced 3.03%	4,443 $80,000
Q3 2018 Nov 15, 2018	SELL	$29.37 - $49.48 $6,314 - $10,638	-215 Reduced 4.48%	4,582 $135,000
Q2 2018 Aug 22, 2018	SELL	$42.06 - $62.4 $2.18 Million - $3.24 Million	-51,871 Reduced 91.53%	4,797 $218,000
Q2 2018 Aug 15, 2018	BUY	$42.06 - $62.4 $2.17 Million - $3.22 Million	51,597 Added 1017.49%	56,668 $218,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $3,458 - $4,672	-69 Reduced 1.34%	5,071 $294,000
Q4 2017 Feb 13, 2018	SELL	$57.69 - $84.58 $5,134 - $7,527	-89 Reduced 1.7%	5,140 $350,000
Q3 2017 Nov 07, 2017	BUY	$67.17 - $84.81 $351,231 - $443,471	5,229	5,229 $431,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.